UGN-101

As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
BioCentury
Tue, 01/8/19 - 11:44 pm
Urogen
UGN-101
MitoGel
urothelial cancer
Liz Barrett
Upcoming events – Phase III readouts loom for Urogen and Mediwound
EP Vantage
Fri, 12/21/18 - 12:04 pm
Urogen
clinical trials
UGN-101
urothelial cancer
MediWound
NexoBrid
devices
burns